Postoperative nivolumab added to standard-of-care adjuvant cisplatin radiotherapy “represents a potential new standard.” ...

Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.

Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell ...

Adding nivolumab to adjuvant CRT improved DFS in patients with locally advanced head and neck squamous cell carcinoma at high risk of relapse.

Researchers are also investigating the PD-1 immune checkpoint inhibitor as treatment before surgical and radiation treatment.

NIVOPOSTOP trial data demonstrate a reduction in the risk of recurrence or death with adjuvant nivolumab combined with ...

Libtayo (cemiplimab) was cleared in 2018 for treating advanced CSCC in patients who are not candidates for curative surgery ...

A five-fraction, one-week schedule of adjuvant breast radiotherapy is as safe and effective as a standard three-week schedule ...

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

Adjuvant therapies are additional treatments, such as chemotherapy or radiation therapy, that help kill remaining cancer cells after primary therapy, like surgery, is complete. Treating breast ...

More information: PORTEC-4a; an international randomised trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer, Radiotherapy and Oncology (2025).